Skip to main content
OpenTrials

Clinical trial condition

Skin Diseases, Vascular

Explore clinical trials studying Skin Diseases, Vascular. Study availability and eligibility vary by location and protocol.

953 public trials 192 recruiting studies
Refine in advanced search Browse all conditions

Skin Diseases, Vascular trial results

Active, Not Recruiting

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405

Conditions
Chronic Disease, Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, +13 more
Locations
  • Allervie Clinical Research Birmingham, Alabama, United States
  • Acuro Research, Inc. Little Rock, Arkansas, United States
  • Modena Allergy & Asthma Clinical Research - La Jolla La Jolla, California, United States
  • Allergy & Asthma Associates of Southern California Laguna Niguel, California, United States
View all 47 locations
View Trial Details
Active, Not Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451

Conditions
Chronic Disease, Chronic Spontaneous Urticaria, Chronic Urticaria, +10 more
Locations
  • Kern Research Bakersfield, California, United States
  • Allergy and Asthma Medical Group and Research Center San Diego, California, United States
  • Pediatric Dermatology of Miami at the Pediatric CoE Miami, Florida, United States
  • Treasure Valley Medical Research Boise, Idaho, United States
View all 50 locations
View Trial Details
Active, Not Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934

Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Autoimmune Diseases, Cardiovascular Diseases, +13 more
Locations
  • GSK Investigational Site Denver, Colorado, United States
  • GSK Investigational Site Gainesville, Florida, United States
  • GSK Investigational Site Rochester, Minnesota, United States
  • GSK Investigational Site New York, United States
View all 63 locations
View Trial Details
Active, Not Recruiting

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941

Conditions
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Autoimmune Diseases, +18 more
Locations
  • Arizona Arthritis and Rheumatology Research PLLC Mesa, Arizona, United States
  • Mayo Clinic Rochester Rochester, Minnesota, United States
  • Novartis Investigative Site CABA, Buenos Aires, Argentina
  • Novartis Investigative Site La Plata, Buenos Aires, Argentina
View all 42 locations
View Trial Details
Active, Not Recruiting

PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS

NCT04664465

Conditions
ANCA Associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Arteritis, +34 more
Locations
  • CHU d'Angers Angers, France
  • CHRU de Brest Brest, France
  • CHD Vendée La Roche-sur-Yon, France
  • CH Le Mans Le Mans, France
View Trial Details
Active, Not Recruiting

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243

Conditions
Chronic Disease, Chronic Inducible Urticaria, Chronic Urticaria, +11 more
Locations
  • Allervie Clinical Research Birmingham, Alabama, United States
  • Acuro Research Inc Little Rock, Arkansas, United States
  • Kern Research Bakersfield, California, United States
  • Allergy and Asthma Specialists Group Huntington Beach, California, United States
View all 131 locations
View Trial Details
Active, Not Recruiting

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

NCT06042478

Conditions
Chronic Disease, Chronic Spontaneous Urticaria, Chronic Urticaria, +10 more
Locations
  • Novartis Investigative Site CABA, Buenos Aires, Argentina
  • Novartis Investigative Site Rosario, Santa Fe Province, Argentina
  • Novartis Investigative Site Bahía Blanca, Argentina
  • Novartis Investigative Site CABA, Argentina
View all 111 locations
View Trial Details

Related conditions